Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

ABT-450

Known as: ABT 450, ABT450 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Macrocyclic Compounds

Narrower (1)

paritaprevir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
In silico studies on therapeutic agents for COVID-19: Drug repurposing approach
Abstract Aims The severe acute respiratory syndrome… 
  • table 2
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2014
Highly Cited
2014
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
BACKGROUND Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased… 
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Highly Cited
2014
Highly Cited
2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
BACKGROUND The interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r) and the NS5A inhibitor… 
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Highly Cited
2014
Highly Cited
2014
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
BACKGROUND The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir with or without ribavirin… 
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2014
Highly Cited
2014
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
BACKGROUND In this phase 3 trial we evaluated the efficacy and safety of the interferon-free combination of ABT-450 with… 
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2014
Highly Cited
2014
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
BACKGROUND & AIMS The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor… 
  • table 1
  • table 2
  • table 3
Highly Cited
2014
Highly Cited
2014
In Vitro and In Vivo Antiviral Activity and Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor ABT-450
ABSTRACT The development of direct-acting antiviral agents is a promising therapeutic advance in the treatment of hepatitis C… 
Highly Cited
2014
Highly Cited
2014
An interferon-free antiviral regimen for HCV after liver transplantation.
BACKGROUND Hepatitis C virus (HCV) infection is the leading indication for liver transplantation worldwide, and interferon… 
  • table 1
  • table 2
  • table 4
  • table 3
Highly Cited
2014
Highly Cited
2014
Therapy of hepatitis C--back to the future.
A book on hepatitis C would read like a marriage of an Orson Welles mystery and a Shakespearean play — awash in enigma, tragedy… 
  • table 1
  • table 1
Highly Cited
2013
Highly Cited
2013
Exploratory study of oral combination antiviral therapy for hepatitis C.
BACKGROUND There is a need for interferon-free treatment regimens for hepatitis C virus (HCV) infection. The goal of this study… 
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE